Email: cspc@cspc.cn
Media
News Center
Mar. 19
2024
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039)OBTAINS CLINICAL TRIAL APPROVAL
Mar. 15
CSPC Innovation Included in FTSE Global Equity Index Series
Stroke: Butylphthalide Improves Post-Stroke Cognitive Impairment in Non-Human Primate
CSPC Acarbose Receives EU GMP Certificate
Two Studies of CSPC Presented at the International Stroke Conference
Feb. 21
Phase III Study of CSPC's Prusogliptin Tablets Published
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
